Immuneering Shares Promising Data on Pancreatic Cancer Treatment
Immuneering Corporation Unveils New Data on Pancreatic Cancer Trials
- Company to hold an investor call on upcoming data -
- Presentation at PanCAN Scientific Summit following data release -
- Deep Cyclic Inhibitors to be reviewed at the RAS-Targeted Drug Development Summit -
CAMBRIDGE, Mass. — Immuneering Corporation (NASDAQ: IMRX) is making strides in the oncology field with its focus on keeping cancer patients alive. The company recently announced its plans to share updated overall survival data from a phase 2a clinical trial involving patients with first-line pancreatic cancer, treated with atebimetinib in combination with modified Gemcitabine/nab-paclitaxel (mGnP).
The upcoming presentation is set to take place on a Thursday following the announcement, with recent data reflecting a median follow-up of nine months involving 34 patients in the trial. This reveal is crucial, especially considering that pancreatic cancer patients face low survival rates with traditional treatments.
Upcoming Presentations and Insights
Immuneering’s commitment to transparency and scientific collaboration is evident in their presentation plans:
Investor Call on September 25
The first key event is an investor call scheduled for 8 a.m. ET where Immuneering will discuss the updated survival data and its implications in the context of pancreatic cancer treatment. This call will be available via a live webcast, allowing stakeholders and interested parties to stay informed.
PanCAN Scientific Summit Presentation
Directly following the investor call, Immuneering will present a poster titled "Atebimetinib + mGnP: Overall Survival and Safety in First-Line Pancreatic Cancer Patients” at the PanCAN Scientific Summit 2025. This summit, aimed at enhancing understanding and treatment of pancreatic cancer, represents a significant opportunity for the company to showcase its findings to healthcare professionals and researchers.
Insights on Preclinical Data
In addition to the aforementioned presentations, Immuneering will also share compelling preclinical data regarding Deep Cyclic Inhibitors at the RAS-Targeted Drug Development Summit. The discussion will emphasize how these novel inhibitors represent a transformative approach in treating RAS-mutant cancers.
According to Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering, the team is eager to share these results. "We are excited to share updated overall survival data from our ongoing Phase 2a trial. Our previous reports have indicated a remarkable 94% overall survival at the six-month mark with the atebimetinib + mGnP regimen. This is substantial when considering that only about 47% survive to nine months with traditional therapies like Gemcitabine/nab-paclitaxel."
Zeskind elaborated on the potential of atebimetinib, highlighting its design for durability, tolerability, and improved patient outcomes. Immuneering aims to shift the paradigm in pancreatic cancer care by addressing common shortcomings found in current treatment options.
About Immuneering Corporation
Immuneering is pioneering a unique category of cancer treatments with its Deep Cyclic Inhibitors, targeting pathways crucial for tumor survival. The lead candidate, atebimetinib (IMM-1-104), demonstrates promising results in improving the treatment landscape for pancreatic cancers.
As the clinical trials for this innovative drug continue to unfold, Immuneering's pipeline remains robust, focusing on early-stage programs alongside its main candidates. Stakeholders and interested parties can visit www.immuneering.com for further information on their research and clinical endeavors.
Frequently Asked Questions
What is Immuneering Corporation known for?
Immuneering Corporation is a clinical-stage oncology company focused on developing innovative cancer treatments, particularly through its unique Deep Cyclic Inhibitors.
When is the investor call taking place?
The investor call is scheduled for 8 a.m. ET, shortly before the updated survival data will be shared.
What are Deep Cyclic Inhibitors?
Deep Cyclic Inhibitors represent a new category of cancer medicines developed by Immuneering, aimed at enhancing treatment durability and tolerability.
Where will Immuneering present its findings?
Immuneering will present its findings at the PanCAN Scientific Summit and the RAS-Targeted Drug Development Summit.
How can I find more information about Immuneering’s clinical trials?
More details about their clinical trials and ongoing research can be found on the company’s official website, www.immuneering.com.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.